ANEB — Anebulo Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $70.11m
- $63.47m
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Total Operating Expenses | 0.173 | 3.61 | 6.83 | 11.8 |
Operating Profit | -0.173 | -3.61 | -6.83 | -11.8 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -0.175 | -30.3 | -6.83 | -11.7 |
Provision for Income Taxes | ||||
Net Income After Taxes | -0.175 | -30.3 | -6.83 | -11.7 |
Net Income Before Extraordinary Items | ||||
Net Income | -0.175 | -30.3 | -6.83 | -11.7 |
Adjustments to Net Income | ||||
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -0.175 | -38.5 | -6.83 | -11.7 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.008 | -1.65 | -0.292 | -0.468 |
Dividends per Share |